SPEN-AS1: A Potential Drug Target and Biomarker (G729614)

Target Name: SPEN-AS1

NCBI ID: G729614

SPEN-AS1

Other Name(s): SPEN antisense RNA 1

SPEN-AS1: A Potential Drug Target and Biomarker

SPEN-AS1, short for SPEN Antisense RNA 1, is a non-coding RNA molecule that has been shown to play a critical role in various biological processes. Its unique structure and function have piqued the interest of researchers, and it has the potential to be a drug target or biomarker.

SPEN-AS1 is a small molecule that is expressed in most tissues and cells. It is composed of a single exon that encodes a RNA molecule that contains a unique sequence of ncRNA. The ncRNA is composed of a series of alternating regions that include a stem -loop, a 5' hat structure and a tail structure. Stem-loop is a structure in RNA molecules that usually contains some base pair modifications and protein binding sites involved in the transcription process. The 5' cap structure is one end of the RNA molecule and is usually the binding site for RNA-binding proteins. The tail structure is the end of the RNA molecule and contains some structures unique to non-coding RNA molecules.

SPEN-AS1 functions as an antisense RNA, meaning that it matches the sequence of the mRNA it is transcribed from, but with the opposite strand. This creates a double-stranded RNA molecule that can act as a protein-mRNA hybrid, and can potentially disrupt the translation of mRNAs into proteins. This is similar to the way that RNA interference (RNAi) works, but on a smaller scale.

SPEN-AS1 has been shown to play a critical role in various biological processes, including cell growth, apoptosis, and transcriptional regulation. It has been shown to regulate the expression of genes involved in cell growth and differentiation, and has been linked to the development and progression of various diseases, including cancer.

SPEN-AS1 has also been shown to have potential as a drug target. By targeting SPEN-AS1, researchers may be able to interfere with its function and potentially treat diseases that are caused by its over-expression or dysfunction. This is because SPEN- AS1 has been shown to play a role in the development and progression of certain diseases, including cancer, and may be a useful target for new therapies.

In addition to its potential as a drug target, SPEN-AS1 also has the potential to be a biomarker. Its unique structure and function make it a promising candidate for use as a diagnostic tool or therapeutic target. This is because SPEN-AS1 has been shown to be expressed in a variety of tissues and cells, and its levels can be easily measured and correlated with other biological metrics.

SPEN-AS1 has also been shown to be expressed in various diseases, including cancer. This suggests that it may be a useful biomarker for the diagnosis and treatment of these diseases. Additionally, its expression has been correlated with the severity of certain diseases, such as cancer, suggesting that it may be a useful target for therapies that aim to improve disease outcomes.

In conclusion, SPEN-AS1 is a non-coding RNA molecule that has the potential to be a drug target or biomarker. Its unique structure and function make it an interesting candidate for both research and clinical applications. Further studies are needed to fully understand its role in various biological processes and its potential as a drug or biomarker.

Protein Name: SPEN Antisense RNA 1

The "SPEN-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPEN-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets